Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | interleukin-1 receptor-associated kinase 4 | Starlite/ChEMBL | References |
Escherichia coli | fused N-acetyl glucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyl transferase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Mycobacterium leprae | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.579 uM | Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | = 0.65 uM | Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after 30 mins by malachite green staining-based assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
PB (ADMET) | > 99 % | Serum protein binding in human at 10 uM after 30 mins by ultrafiltration method | ChEMBL. | 25262942 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.